BRAF anticorps

N° du produit ABIN7880047

Cet anticorps anti-BRAF Monoclonal Souris (Clone BRAF-1626) (ABIN7880047) détecte spécifiquement BRAF dans IHC (p). L’anticorps est réactif avec des échantillons de Humain.

Aperçu rapide pour BRAF anticorps (ABIN7880047)

Antigène: BRAF (B-Raf proto-oncogene, serine/threonine kinase (BRAF))

Reactivité: Humain

Hôte: Souris

Clonalité: Monoclonal

Conjugué: Cet anticorp BRAF est non-conjugé

Application: Immunohistochemistry (Paraffin-embedded Sections) (IHC (p))

Classe de qualité: Carrier-free

Clone: BRAF-1626

Détail du produit anti-BRAF anticorps

Fonction: BRAF Antibody (azide and preservative free)

Purification: Protein A/G affinity

Immunogène: A recombinant fragment of human HMG20B/BRAF protein was used as the immunogen for the BRAF antibody.

Isotype: IgG1, kappa

Information d'application

Indications d'application: Optimal dilution of the BRAF antibody should be determined by the researcher.

Restrictions: For Research Use only

Stockage

Format: Liquid

Concentration: 1 mg/mL

Buffer: 1 mg/mL in 1X PBS, BSA free, sodium azide free

Agent conservateur: Azide free

Stock: -20 °C

Stockage commentaire: Aliquot the BRAF antibody and store frozen at -20oC or colder. Avoid repeated freeze-thaw cycles.

Détails sur BRAF

Antigène: BRAF (B-Raf proto-oncogene, serine/threonine kinase (BRAF))

Autre désignation: BRAF

Sujet: The BRAF gene encodes a cytoplasmic serine-threonine kinase, which initiates the activation of the mitogen-activated protein kinase (MAPK) signalling pathway. The oncogenic mutations in the kinase region of BRAF gene result in constitutive activation of the MAPK signalling pathway, leading to increased cell proliferation, resistance to apoptosis and tumor progression. The most common of all activating BRAF mutations leads to a substitution of valine (V) to glutamic acid (E) at the position 600 of the amino acid sequence. The BRAF V600E mutation is an important predictive and prognostic biomarker. The BRAF V600E mutation is detected in approximately 8 % of all solid tumours, including 45 % of papillary thyroid carcinomas, 40-60 % of melanomas, 5-15 % of colorectal adenocarcinomas, 35 % of serous low grade and borderline ovarian carcinomas, 1-3 % of non-small cell lung cancers, and 5-7 % of cholangiocarcinomas. Furthermore, the BRAF V600E mutation is found in 100 % of hairy cell leukaemia, 54 % Erdheim-Chester disease, 38 % of Langerhans cell histocytoses and 60 % of pleomorphic xanthoastrocytomas.

UniProt: Q9P0W2

Pathways: Signalisation MAPK, Signalisation RTK, Neurotrophin Signaling Pathway, Ribonucleoprotein Complex Subunit Organization, Hepatitis C, Autophagy